Phacolytic Glaucoma Medication

  • Author: Kayoung Yi, MD, PhD; Chief Editor: Hampton Roy Sr, MD   more...
 
Updated: Jul 6, 2011
 

Medication Summary

Several applications of a topical beta-blocker, a topical alpha2-adrenergic, a topical carbonic anhydrase inhibitor, and a topical corticosteroid should be started in the office on presentation when possible. The IOP should be remeasured in 30 minutes to 1 hour. If the IOP is severely elevated or is nonresponsive to initial topical medications, a systemic carbonic anhydrase inhibitor and an osmotic agent also should be administered. The latter medications may be administered intravenously if the patient is nauseated or vomiting. Prostaglandin analogs (eg, Xalatan, Rescula, Lumigan, Travatan) may not be as useful in the treatment of phacolytic glaucoma (PG) because of their slow onset of action and their theoretical risk of exacerbating intraocular inflammation.[16] The adequacy of initial response to medical therapy helps to determine the urgency of scheduling cataract extraction.

Next

Beta-blockers

Class Summary

The exact mechanism of ocular antihypertensive action is not established, but it appears to be a reduction of aqueous humor production.

Timolol maleate or hemihydrate (Timoptic XE, Timoptic, Betimol)

 

May reduce elevated and normal IOP, with or without glaucoma, by inhibiting inflow.

Levobunolol (AKBeta, Betagan)

 

Nonselective beta-adrenergic blocking agent that lowers IOP by reducing aqueous humor production

Carteolol ophthalmic (Ocupress)

 

Blocks beta1- and beta2-receptors and has mild intrinsic sympathomimetic effects.

Betaxolol ophthalmic (Betoptic)

 

Selectively blocks beta1-adrenergic receptors with little or no effect on beta2-receptors. Reduces IOP by reducing production of aqueous humor.

Metipranolol hydrochloride (OptiPranolol)

 

Beta-adrenergic blocker that has little or no intrinsic sympathomimetic effects and membrane-stabilizing activity. Has little local anesthetic activity. Reduces IOP by reducing production of aqueous humor.

Previous
Next

Topical alpha2-adrenergics agonists

Class Summary

May reduce elevated and normal IOP, with or without glaucoma, by inhibiting inflow.

Apraclonidine (Iopidine)

 

Reduces elevated and normal IOP whether or not accompanied by glaucoma. Apraclonidine is a relatively selective alpha-adrenergic agonist that does not have significant local anesthetic activity. Has minimal cardiovascular effects.

Brimonidine (Alphagan)

 

Selective alpha2-receptor that reduces aqueous humor formation and may increase uveoscleral outflow.

Previous
Next

Carbonic anhydrase inhibitors

Class Summary

By slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport, it may inhibit carbonic anhydrase in the ciliary processes of the eye. This effect decreases aqueous humor secretion, reducing IOP.

Dorzolamide (Trusopt)

 

Used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one ophthalmic drug is being used, administer the drugs at least 5 min apart. Reversibly inhibits carbonic anhydrase, reducing hydrogen ion secretion at renal tubule and increasing renal excretion of sodium, potassium bicarbonate, and water to decrease production of aqueous humor.

Brinzolamide (Azopt)

 

Catalyzes reversible reaction involving hydration of carbon dioxide and dehydration of carbonic acid. May use concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, administer drugs at least 5 min apart.

Acetazolamide (Diamox, Diamox Sequels)

 

Inhibits enzyme carbonic anhydrase, reducing rate of aqueous humor formation, which, in turn, reduces IOP. Used for adjunctive treatment of chronic simple (open-angle) glaucoma and secondary glaucoma and preoperatively in acute angle-closure glaucoma when delay of surgery desired to lower IOP.

Methazolamide (Neptazane)

 

Reduces aqueous humor formation by inhibiting enzyme carbonic anhydrase, which results in decreased IOP.

Previous
Next

Hyperosmotic agents

Class Summary

Create an osmotic gradient between ocular fluids and plasma. Not for long-term use.

Glycerin (50% solution prepared from Glycerin USP [450 mL, Humco, Texarkana, TX] and sterile water)

 

Used in glaucoma to interrupt acute attacks. Oral osmotic agent for reducing IOP. Able to increase tonicity of blood until finally metabolized and eliminated by the kidneys. Maximum reduction of IOP usually occurs 1 h after glycerin administration. Effect usually lasts approximately 5 h.

Mannitol (Osmitrol)

 

Reduces elevated IOP when pressure cannot be lowered by other means. Initially assess for adequate renal function in adults by administering a test dose of 200 mg/kg, given IV over 3-5 min. Should produce a urine flow of at least 30-50 mL/h of urine over 2-3 h. In children, assess for adequate renal function by administering a test dose of 200 mg/kg, given IV over 3-5 minutes. Should produce a urine flow of at least 1 mL/h over 1-3 h.

Previous
Next

Corticosteroids

Class Summary

Reduce eye pain and intraocular inflammation.

Prednisolone ophthalmic (Pred Forte)

 

Treats acute inflammation following eye surgery or other types of insults to eye. Decreases inflammation and corneal neovascularization. Suppresses migration of polymorphonuclear leukocytes and reverses increased capillary permeability. In cases of bacterial infections, concomitant use of anti-infective agents is mandatory; if signs and symptoms do not improve after 2 days, reevaluate patient. Dosing may be reduced, but advise patients not to discontinue therapy prematurely.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Kayoung Yi, MD, PhD  Associate Professor, Department of Ophthalmology, Hallym University, Kangnam Sacred Heart Hospital, Korea

Kayoung Yi, MD, PhD is a member of the following medical societies: American Society of Cataract and Refractive Surgery and Korean Board of Ophthalmology

Disclosure: Nothing to disclose.

Coauthor(s)

Teresa C Chen, MD, FACS  Assistant Professor, Department of Ophthalmology, Harvard Medical School; Director of Clinical Affairs, Glaucoma Service, Consulting Staff, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary

Teresa C Chen, MD, FACS is a member of the following medical societies: Alpha Omega Alpha, American Academy of Ophthalmology, American College of Surgeons, American Medical Association, Association for Research in Vision and Ophthalmology, Massachusetts Medical Society, and Women in Ophthalmology, Inc

Disclosure: Nothing to disclose.

Specialty Editor Board

Richard W Allinson, MD  Associate Professor, Department of Ophthalmology, Texas A&M University Health Science Center; Senior Staff Ophthalmologist, Scott and White Clinic

Richard W Allinson, MD, is a member of the following medical societies: American Academy of Ophthalmology, American Medical Association, and Texas Medical Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Martin B Wax, MD  Clinical Professor, Department of Ophthalmology, University of Texas Southwestern Medical School; Vice President, Ophthalmology Research and Development, Head, Ophthalmology Discovery Research, Alcon Labs, Inc

Martin B Wax, MD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, and Society for Neuroscience

Disclosure: Nothing to disclose.

Lance L Brown, OD, MD  Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri

Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy Sr, MD  Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

References
  1. Kanski JJ. Lens-related glaucoma. In: Clinical Ophthalmology. 5th ed. 2003:239.

  2. Richter C. Lens-induced open angle glaucoma: phacolytic glaucoma (lens protein glaucoma). In: Ritch R, Shields MB, Krupin T, eds. The Glaucomas. 2nd ed. St Louis: Mosby; 1996:1023-1026.

  3. Stamper R, Lieberman M, Drake M. Secondary open-angle glaucoma: phacolytic glaucoma. In: Becker-Shaffer's Diagnosis and Therapy of the Glaucomas. 7th ed. St Louis, Mo: Mosby; 1999:324-326.

  4. Kim IT, Jung BY, Shim JY. Cholesterol crystals in aqueous humor of the eye with phacolytic glaucoma. J Korean Ophthalmol Soc. Sept 2000;41(9):2003-7.

  5. Mavrakanas N, Axmann S, Issum CV, Schutz JS, Shaarawy T. Phacolytic Glaucoma: Are There 2 Forms?. J Glaucoma. Mar 16 2011;[Medline].

  6. Pradhan D, Hennig A, Kumar J. A prospective study of 413 cases of lens-induced glaucoma in Nepal. Indian J Ophthalmol. 2001;Jun;49(2):103-7. [Medline].

  7. Mandal AK, Gothwal VK. Intraocular pressure control and visual outcome in patients with phacolytic glaucoma managed by extracapsular cataract extraction with or without posterior chamber intraocular lens implantation. Ophthalmic Surg Lasers. Nov 1998;29(11):880-9. [Medline].

  8. Allingham RR, Damji KD, Freedman S. Glaucomas associated with disorders of the lens: phacolytic (lens protein) glaucoma. In: Shields Textbook of Glaucoma. 2005. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 262-3.

  9. Chu ER, Durkin SR, Keembiyage RD, Nathan F, Raymond G. Nineteen-year delayed-onset phacolytic uveitis following dislocation of the crystalline lens. Can J Ophthalmol. Feb 2009;44(1):112. [Medline].

  10. Gadia R, Sihota R, Dada T, Gupta V. Current profile of secondary glaucomas. Indian J Ophthalmol. Jul-Aug 2008;56(4):285-9. [Medline].

  11. Sihota R, Kumar S, Gupta V, Dada T, Kashyap S, Insan R, et al. Early predictors of traumatic glaucoma after closed globe injury: trabecular pigmentation, widened angle recess, and higher baseline intraocular pressure. Arch Ophthalmol. Jul 2008;126(7):921-6. [Medline].

  12. Alliman KJ, Smiddy WE, Banta J, Qureshi Y, Miller DM, Schiffman JC. Ocular trauma and visual outcome secondary to paintball projectiles. Am J Ophthalmol. Feb 2009;147(2):239-242.e1. [Medline].

  13. Braganza A, Thomas R, George T. Management of phacolytic glaucoma: experience of 135 cases. Indian J Ophthalmol. Sep 1998;46(3):139-43. [Medline].

  14. Chen TC. Lens-induced glaucomas: surgical techniques and complications. Middle East J Ophthalmol. May 2004;12(1):40-52.

  15. Venkatesh R, Tan CS, Kumar TT, Ravindran RD. Safety and efficacy of manual small incision cataract surgery for phacolytic glaucoma. Br J Ophthalmol. Mar 2007;91(3):279-81. [Medline]. [Full Text].

  16. Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol. Nov 2008;53 Suppl1:S93-105. [Medline].

Previous
Next
 
Microscopy of the aspirate at the time of cataract extraction shows clumped, notched rectangular platelike crystals from the aqueous of a patient with phacolytic glaucoma (X160). Reproduced from J Korean Ophthalmol Soc 2000 Sep;41(9): Copyright © 2000, Korean Ophthalmological Society. All rights reserved.
Microscopy of the aspirate at the time of cataract extraction of a patient with phacolytic glaucoma shows round, regular cells with foamy cytoplasm consistent with macrophages (*). A leukocyte (white arrow) and an erythrocyte (black arrow) also are seen (X160). Reproduced from J Korean Ophthalmol Soc 2000 Sep;41(9): Copyright © 2000, Korean Ophthalmological Society. All rights reserved.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.